Pulsating Growth

Dr A Velumani

At the Diagnostics Leadership Summit, Dr A Velumani, Creator, Thyrocare, spoke about his journey and the blessings in disguise ushered in by the Covid-19 pandemic. eHEALTH was the co-organiser of DLS virtual.


Born to a farmer family near Coimbatore in Tamil Nadu, Arokiaswamy Velumani went on to be a doyen of the Indian Diagnostics industry. After completing his graduation, Velumani joined a small pharma company Gemini Capsules in 1979 in his home district. Later, he moved on to Bhabha Atomic Research Centre (BARC) as a laboratory assistant and climbed the ladder to be in the rank of a scientist. Then he was posted at BARC’s Radiation Medicine Centre (RMC) of Tata Memorial Hospital in Mumbai, he narrated to the Live audience.

In 1996, Velumani took the entrepreneurial route to start his thyroid testing laboratory, Thyrocare. He drew up a franchise model for his business and created a niche for himself by offering affordable testing services. Soon, Thyrocare began to expand from thyroid disorder testing to preventive medical checkups, among others, he reflected.

When the Covid-19 pandemic struck India and the government permitted labs to conduct RTPCR tests for Covid-19, Velumani said that Thyrocare was featured first on the list. “There was a huge lockdown and emotional pressure, besides safety concerns of employees.” He emphasised that the company came out with flying colours by delivering desired results with the help of employees who “literally” did not go home for 2-3 months. Their hard work paid off, and the company witnessed unprecedented growth. The Covid, he remarked, brought prosperity in the form of RT-PCR tests. “We had 30% quarter-over-quarter growth of Q2 in FY’21 and there are labs that had 300% growth. There were roughly 20 crore tests conducted in the country. So, the industry witnessed growth during the unprecedented times,” he quipped.


Follow and connect with us on Facebook, Twitter, LinkedIn, Elets video

Eletsonline News

Follow us on

Most Popular

200000+ Subscribers read it every day.
Subscribe Newsletter
To Top